The Rx Consultant: The fasted way to stay up-to-date on drug therapy and reviews

Every Subscription Includes:

Drug Therapy Updates & Reviews
Every article tells you what's new - and gives you a streamlined review
FREE CE
It's information that you can trust - independently researched and written. No drug industry money or influence
Healthcare News
Keeps you up-to date on the news that matters most - so you will have the answers before you are asked
Patient Q&A Summary Pages
Answers common questions and gives you the key counseling points, so you can streamline patient education
Quick Reference Cards
It's just what you need when you want to check your facts, verify a dose, or give a quick answer.

Untitled Document

News:

Tight Glucose Control Does Not Decrease CV Events

The results of 2 large studies have shown that aggressively lowering blood sugar to near normal levels in type 2 diabetics does not prevent complications such as stroke and heart attack. Patients in the studies averaged 62-66 years of age, had a 8-10 year history of diabetes, and an average hemoglobin A1C of 7.5%-8.3%. About one third of them had a history of cardiovascular disease.

The ACCORD study randomized patients to intensive therapy to achieve a target A1C of less than 6.0%, or standard therapy targeting an A1C of 7.0 to 7.9%...
Continue

An Excerpt From The July Edition:

An Evolving View of Menopausal Hormone Therapy

The controversy over the beneficial effects and safety of hormone therapy (HT) has swung like a pendulum over the last 30 years. Oral conjugated estrogens were first marketed for menopausal symptom relief in the 1930’s. In the 1970’s, HT was cast in a new role as a health-promoting therapy after studies suggested it reduces the risk of heart disease, osteoporosis, and Alzheimer’s disease. Many more women started using HT and were encouraged to do so by their prescribers.

In the 1990’s, 2 large clinical trials evaluated HT for the prevention of cardiovascular disease. Unexpectedly, these trials found NO reduction in risk. In fact, the results suggested HT may actually increase the risk of heart disease and breast cancer. Within 6 months after these results were published, more than half of American women who were taking HT stopped.

Over the last 3 years, provocative new information has been published suggesting HT may be safer in some women than previously thought. While guidelines, package inserts and “black-box” warnings have not yet changed, the consensus of expert opinion on HT appears to be shifting.

This issue will bring you up to date on the risk-benefit profile of HT, including newer information about the risks of heart disease and breast cancer. The established benefits of HT are reviewed, and current recommendations for use are summarized. Tables provide a quick guide to available products and usual doses. The Patient Connection answers questions women frequently ask about HT and includes an inset to help you quickly identify those who should avoid estrogen.